Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get trading ideas, historical data, advanced options screeners, more. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Edgewise Therapeutics Inc (EWTX)

Edgewise Therapeutics Inc (EWTX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 678,286
  • Shares Outstanding, K 63,214
  • Annual Sales, $ 0 K
  • Annual Income, $ -42,810 K
  • 60-Month Beta -0.08
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.42
Trade EWTX with:

Options Overview Details

View History
  • Implied Volatility 85.45% ( +0.42%)
  • Historical Volatility 64.68%
  • IV Percentile 53%
  • IV Rank 55.95%
  • IV High 151.82% on 08/10/22
  • IV Low 1.15% on 09/09/22
  • Put/Call Vol Ratio 0.00
  • Today's Volume 0
  • Volume Avg (30-Day) 5
  • Put/Call OI Ratio 1.36
  • Today's Open Interest 532
  • Open Int (30-Day) 497

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/22
See More
  • Average Estimate -0.36
  • Number of Estimates 3
  • High Estimate -0.33
  • Low Estimate -0.39
  • Prior Year -0.26
  • Growth Rate Est. (year over year) -38.46%

Price Performance

See More
Period Period Low Period High Performance
1-Month
8.79 +16.72%
on 01/11/23
11.48 -10.63%
on 01/17/23
+0.84 (+8.92%)
since 01/06/23
3-Month
7.05 +45.64%
on 12/19/22
11.48 -10.63%
on 01/17/23
+0.66 (+6.87%)
since 11/08/22
52-Week
5.41 +89.82%
on 05/25/22
14.33 -28.40%
on 09/12/22
-2.45 (-19.28%)
since 02/08/22

Most Recent Stories

More News
Edgewise Therapeutics to Present at the SVB Securities Global Biopharma Conference on February 14, 2023

Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, targeted, small molecule therapies for the treatment of devastating muscle...

EWTX : 10.26 (-4.38%)
Edgewise Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023

Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, targeted, small molecule therapies for the treatment of devastating muscle...

EWTX : 10.26 (-4.38%)
Edgewise Therapeutics to Showcase Novel Cardiac Program at Virtual Investor Event on Tuesday, January 3, 2023

Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, targeted, small molecule therapies for the treatment of devastating muscle...

EWTX : 10.26 (-4.38%)
Edgewise Therapeutics Appoints Marc Semigran, M.D., As Chief Development Officer

Edgewise Therapeutics, Inc. (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, targeted, small molecule therapies for individuals with devastating muscle...

EWTX : 10.26 (-4.38%)
Wall Street Analysts Believe Edgewise Therapeutics, Inc. (EWTX) Could Rally 133%: Here's is How to Trade

The mean of analysts' price targets for Edgewise Therapeutics, Inc. (EWTX) points to a 133.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement...

EWTX : 10.26 (-4.38%)
Edgewise Therapeutics to Present at Upcoming Investor Conferences

Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for the treatment of rare muscle disorders, announced...

EWTX : 10.26 (-4.38%)
Edgewise Therapeutics Reports Third Quarter 2022 Financial Results

Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for the treatment of rare muscle disorders, today...

EWTX : 10.26 (-4.38%)
Edgewise Therapeutics Announces Initiation of LYNX Phase 2 Clinical Trial of EDG-5506 for the Treatment of Duchenne Muscular Dystrophy (DMD)

Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for the treatment of rare muscle disorders, today...

EWTX : 10.26 (-4.38%)
Edgewise Therapeutics, Inc. (EWTX) Upgraded to Buy: Here's What You Should Know

Edgewise Therapeutics, Inc. (EWTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

EWTX : 10.26 (-4.38%)
Wall Street Analysts Believe Edgewise Therapeutics, Inc. (EWTX) Could Rally 157%: Here's is How to Trade

The consensus price target hints at a 156.9% upside potential for Edgewise Therapeutics, Inc. (EWTX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in...

EWTX : 10.26 (-4.38%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Edgewise Therapeutics Inc. is a clinical-stage biopharmaceutical company. It is focused on developing orally bioavailable, small molecule therapies for rare muscle disorders. Edgewise Therapeutics Inc. is based in Boulder, United States.

See More

Key Turning Points

3rd Resistance Point 11.24
2nd Resistance Point 11.03
1st Resistance Point 10.64
Last Price 10.26
1st Support Level 10.05
2nd Support Level 9.84
3rd Support Level 9.45

See More

52-Week High 14.33
Fibonacci 61.8% 10.92
Last Price 10.26
Fibonacci 50% 9.87
Fibonacci 38.2% 8.81
52-Week Low 5.41

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar